Shufro Rose & Co. LLC Has $382,000 Holdings in Abbott Laboratories (NYSE:ABT)

Shufro Rose & Co. LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 20.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,469 shares of the healthcare product maker’s stock after purchasing an additional 600 shares during the period. Shufro Rose & Co. LLC’s holdings in Abbott Laboratories were worth $382,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ABT. Meridian Wealth Partners LLC boosted its position in shares of Abbott Laboratories by 9.2% during the 4th quarter. Meridian Wealth Partners LLC now owns 3,096 shares of the healthcare product maker’s stock worth $341,000 after acquiring an additional 262 shares in the last quarter. Little House Capital LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $301,000. Legacy Capital Wealth Partners LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $618,000. Stonebrook Private Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $489,000. Finally, PGGM Investments boosted its position in shares of Abbott Laboratories by 144.5% during the 4th quarter. PGGM Investments now owns 647,992 shares of the healthcare product maker’s stock worth $71,324,000 after acquiring an additional 382,980 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the completion of the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the executive vice president now directly owns 78,704 shares of the company’s stock, valued at $9,444,480. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $118.50, for a total value of $55,932.00. Following the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The disclosure for this sale can be found here. Insiders sold a total of 13,935 shares of company stock valued at $1,670,048 over the last ninety days. 0.47% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ABT shares. Evercore ISI increased their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Raymond James reissued a “buy” rating and issued a $124.00 price objective on shares of Abbott Laboratories in a research note on Wednesday, April 24th. Citigroup increased their price objective on shares of Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada dropped their price objective on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday, April 18th. Finally, Barclays dropped their price objective on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research note on Monday, April 22nd. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $121.50.

Abbott Laboratories Stock Down 0.0 %

Shares of Abbott Laboratories stock opened at $107.51 on Monday. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The stock’s 50-day moving average is $113.64 and its 200 day moving average is $108.22. The firm has a market cap of $186.55 billion, a price-to-earnings ratio of 33.50, a PEG ratio of 2.59 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The business had revenue of $9.96 billion for the quarter, compared to the consensus estimate of $9.88 billion. During the same period in the prior year, the business earned $1.03 EPS. The firm’s revenue for the quarter was up 2.2% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.05%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.